Acetaminophen use during pregnancy and offspring attention deficit hyperactivity disorder - a longitudinal sibling control study.
ADHD
MoBa
acetaminophen
pregnancy
sibling control
Journal
JCPP advances
ISSN: 2692-9384
Titre abrégé: JCPP Adv
Pays: United States
ID NLM: 9918250414706676
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
04
03
2021
accepted:
21
04
2021
medline:
22
6
2021
pubmed:
22
6
2021
entrez:
11
7
2023
Statut:
epublish
Résumé
Maternal acetaminophen use during pregnancy is associated with increased risk of ADHD in the child. This could reflect causal influence of acetaminophen on fetal neurodevelopment or could be due to confounding factors. The aim of the current study was to examine unmeasured familial confounding factors of this association. We used data from 26,613 children from 12,902 families participating in the prospective Norwegian Mother, Father, and Child Cohort Study (MoBa). The MoBa was linked to the Norwegian Medical Birth Register and the Norwegian Patient Registry. Siblings discordant for prenatal acetaminophen exposure were compared regarding risk of having an ADHD diagnosis. Children exposed to acetaminophen up to 28 days during pregnancy did not have increased risk of receiving an ADHD diagnosis compared to unexposed children. The adjusted Hazard ratio (aHR) was 0.87 (95% C.I. = 0.70-1.08) for exposure 1 to 7 days, and 1.13 (95% C.I. = 0.82-1.49) for 8-28 days. Long-term exposure (29 days or more) was associated with a two-fold increase in risk of ADHD diagnosis (aHR = 2.02, 95% C.I = 1.17-3.25). In the sibling control model, the association between long-term acetaminophen use and ADHD in the child was aHR = 2.77 (95% C.I. = 1.48-5.05) at the between-family level, and aHR = 1.06 (95% C.I. = 0.51-2.05) at the within-family level. Both the exposed and the unexposed children of mothers with long-term use of acetaminophen in one of the pregnancies had increased risk of receiving an ADHD diagnosis. This indicates that the observed association between long-term acetaminophen use during pregnancy and ADHD in the child may at least partly be confounded by unobserved family factors.
Sections du résumé
Background
UNASSIGNED
Maternal acetaminophen use during pregnancy is associated with increased risk of ADHD in the child. This could reflect causal influence of acetaminophen on fetal neurodevelopment or could be due to confounding factors. The aim of the current study was to examine unmeasured familial confounding factors of this association.
Methods
UNASSIGNED
We used data from 26,613 children from 12,902 families participating in the prospective Norwegian Mother, Father, and Child Cohort Study (MoBa). The MoBa was linked to the Norwegian Medical Birth Register and the Norwegian Patient Registry. Siblings discordant for prenatal acetaminophen exposure were compared regarding risk of having an ADHD diagnosis.
Results
UNASSIGNED
Children exposed to acetaminophen up to 28 days during pregnancy did not have increased risk of receiving an ADHD diagnosis compared to unexposed children. The adjusted Hazard ratio (aHR) was 0.87 (95% C.I. = 0.70-1.08) for exposure 1 to 7 days, and 1.13 (95% C.I. = 0.82-1.49) for 8-28 days. Long-term exposure (29 days or more) was associated with a two-fold increase in risk of ADHD diagnosis (aHR = 2.02, 95% C.I = 1.17-3.25). In the sibling control model, the association between long-term acetaminophen use and ADHD in the child was aHR = 2.77 (95% C.I. = 1.48-5.05) at the between-family level, and aHR = 1.06 (95% C.I. = 0.51-2.05) at the within-family level.
Conclusions
UNASSIGNED
Both the exposed and the unexposed children of mothers with long-term use of acetaminophen in one of the pregnancies had increased risk of receiving an ADHD diagnosis. This indicates that the observed association between long-term acetaminophen use during pregnancy and ADHD in the child may at least partly be confounded by unobserved family factors.
Identifiants
pubmed: 37431475
doi: 10.1002/jcv2.12020
pii: JCV212020
pmc: PMC10242945
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12020Informations de copyright
© 2021 The Authors. JCPP Advances published by John Wiley & Sons Ltd on behalf of Association for Child and Adolescent Mental Health.
Déclaration de conflit d'intérêts
Eivind Ystrom is Joint Editor for JCPP Advances. The remaining authors have declared that they have no competing or potential conflicts of interest. [Corrections made on 22 June 2022, after first online publication: This Conflict of Interest Statement has been updated in this version.]
Références
Int J Epidemiol. 2016 Dec 1;45(6):1987-1996
pubmed: 27353198
JAMA Psychiatry. 2019 Aug 1;76(8):834-842
pubmed: 31042271
BMJ Open. 2014 Feb 17;4(2):e004365
pubmed: 24534260
Paediatr Perinat Epidemiol. 2020 May;34(3):309-317
pubmed: 31916282
JAMA Pediatr. 2020 Nov 1;174(11):1073-1081
pubmed: 32986124
Epidemiology. 2012 Sep;23(5):713-20
pubmed: 22781362
J Child Psychol Psychiatry. 2016 Apr;57(4):540-8
pubmed: 26530451
Int J Epidemiol. 2016 Dec 1;45(6):2009-2017
pubmed: 28031314
Pediatrics. 2017 Feb;139(2):
pubmed: 28138005
Twin Res Hum Genet. 2019 Oct;22(5):290-296
pubmed: 31559947
Epidemiology. 2017 Jul;28(4):540-547
pubmed: 28575894
JAMA Pediatr. 2014 Apr;168(4):313-20
pubmed: 24566677
Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):253-9
pubmed: 16611199
Epidemiology. 2016 Nov;27(6):852-8
pubmed: 27488059
Stat Med. 2003 Aug 30;22(16):2591-602
pubmed: 12898546
Med Hypotheses. 2012 Feb;78(2):351
pubmed: 22154541
Paediatr Perinat Epidemiol. 2020 May;34(3):247-256
pubmed: 31448449
Int J Epidemiol. 2006 Oct;35(5):1146-50
pubmed: 16926217
PLoS One. 2014 Sep 24;9(9):e108210
pubmed: 25251831
Am J Epidemiol. 2019 Apr 1;188(4):768-775
pubmed: 30923825
BMC Med Res Methodol. 2019 Jun 13;19(1):120
pubmed: 31195998
Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):140-147
pubmed: 29044735
Acta Psychiatr Scand. 1993 May;87(5):364-7
pubmed: 8517178
Eur J Epidemiol. 2019 Oct;34(10):927-938
pubmed: 31451995
Paediatr Perinat Epidemiol. 2009 Nov;23(6):597-608
pubmed: 19840297
J Clin Psychiatry. 2019 Sep 10;80(5):
pubmed: 31509360
Am J Epidemiol. 2018 Aug 1;187(8):1817-1827
pubmed: 29688261
BMC Psychiatry. 2017 Jan 17;17(1):23
pubmed: 28095819
Mol Psychiatry. 2019 Apr;24(4):562-575
pubmed: 29892054
Pediatrics. 2017 Nov;140(5):
pubmed: 29084830
Int J Epidemiol. 2013 Dec;42(6):1702-13
pubmed: 24163279
JAMA Pediatr. 2016 Oct 01;170(10):964-970
pubmed: 27533796
Int J Epidemiol. 2016 Apr;45(2):382-8
pubmed: 27063603
JAMA Pediatr. 2014 Apr;168(4):306-7
pubmed: 24566519